This table lists all the major pharma collaborations, acquisitions and mergers agreed during September 2013.
For an indepth analysis of these deals, read ‘Pharma deals during September 2013’
|
Licensor acquired / licensee acquirer |
Deal type |
Product / technology |
Headline ($m) |
|||
| GlaxoSmithKline / Suntory Beverage & Food | Acquisition of assets | Lucozade and Ribena soft drink brands | 2,116 | |||
| Adcock Ingram / CFR Pharmaceuticals | Acquisition |
|
1,262 | |||
| Astex Pharma / Otsuka Pharma | Acquisition | Oncology biotech company | 886 | |||
| Ablynx / AbbVie1 | Licence |
|
840 | |||
| GSK / Aspen Pharmacare | Acquisition of assets2 | Arixtra and Fraxiparine – anti-thrombotic agents | 700 | |||
| Gland Pharma / KKR | Acquisition (40 per cent) | Indian generics company | 500 | |||
| Egis / Servier | Acquisition (49 per cent)3 | Hungarian pharmaceutical company | 483 | |||
| BioFire Diagnostics / BioMerieux | Acquisition | Invitro diagnostic company | 450 | |||
| Inovio Pharma / Roche Holdings | Licence | DNA immunoptherapy vaccines targeting prostate cancer (INO5150) and Hepatitis B (INO-1800), plus CELECTRA delivery technology | 423 | |||
| Galapagos / AbbVie | Global alliance | Novel potentiator / combination therapies in cystic fibrosis focussing on F508del and G551D mutations | 405 | |||
| Medytox / Allergan4 | Licence | Neurotoxin product candidates | 362 | |||
| Isis Pharma / Biogen Idec | Technology alliance | Antisense technology focusing on therapies for neurological diseases | 320 | |||
| Cornerstone Therapeutics/ Chiesi Farmaceutici | Acquisition (42 per cent) | US speciality pharmaceutical company focused hospital and niche respiratory products | 255 | |||
| Coherus Biosciences / Baxter International | Licence | Etanercept biosimilar for rhematoid arthritis | 246 | |||
| Laboratorios Casen Fleet/ Recordati | Acquisition | Spanish pharmaceutical company | 123 | |||
| Pacific Biosciences of California/Roche Diagnostics | Licence | Diagnostic products IVD | 75 | |||
| Merck & Co / AstraZeneca | Licence | WEE1 kinase (MK-1775) for ovarian cancer | 505 | |||
| Shin Nippon Biomedical / Transcept Pharma | Licence | TO-2070 nasal powder for acute migraine | 43 | |||
| Innovus Pharma / Ovation Pharma | Licence | EjectDelay / CIRCUMserum | 39 | |||
| Ablynx / Merck Serono | Research alliance | Use of nanobody platform across Merck Serono’s core disease areas (oncology, immuno-oncology, immunology and neurology) | 33 |
Notes
1. Global option to in-licence product … Ablynx to retain co-promotion rights in Belgium, Netherlands and Luxembourg
2. Global rights excluding India, Pakistan and China
3. Acquisition of the shares not already owned by Servier and Chiesi, ie 51 per cent in Egis and 58 per cent of Cornerstone Therapeutics, respectively
4. Global rights excluding South Korea
5. Only upfront of $50m is disclosed, but Merck will be eligible to receive future payments tied to development and regulatory milestones plus sales-related payments and tiered royalties.